Calidi Biotherapeutics, Inc. Share Price

Calidi Biotherapeutics, Inc. Share Price

AMEX: CLDI
$0.00
+0.00 (0.00%)
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Calidi Biotherapeutics, Inc. Stock Performance

Open
N/A
Prev. Close
N/A
Circuit Range
N/A
Day Range
N/A
Year Range
N/A
Volume
N/A
Average Traded
N/A

Calidi Biotherapeutics, Inc. Share Price Chart

Line chart of the Calidi Biotherapeutics, Inc. price trend over the selected period. The price rose overall, ranging from 0.68 to 0.68, ending at 0.68.
$0.00$0.00
L
Show Current Price
H

Calidi Biotherapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-9.08
Revenue (TTM)
$0.00
Return On Equity (TTM)
-748.64%
Profit Margin
N/A
Debt to Equity
0.30
Quarterly Earnings Growth YoY
61.55%

Calidi Biotherapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$10.82-$4.06-$4.42-$4.16
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A62.48%-8.87%5.88%

Calidi Biotherapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars202320242025
Revenue$0.00$0.00$0.00
Net Profit-$29.22-$23.81-$25.58
Net Profit MarginN/AN/AN/A
Income ChangeN/A18.51%-7.43%

About Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.

Calidi Biotherapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %

CLDI Share Price FAQs